, /PRNewswire/ -- Allied Market Research published a report, titled, " by Indication (Congenital Fibrinogen Deficiency and Surgical Procedure), Form (Lyophilized, Powder, and Liquid), and End User (Hospitals, Ambulatory Surgical Centers, and Others): Global Opportunity Analysis and Industry Forecast, 2024-2035". According to the report, the "human fibrinogen concentrate market" was valued at in 2023, and is estimated to reach by 2035, growing at a CAGR of 11% from 2024 to 2035. The human fibrinogen concentrate market is on a steady growth propelled by several pivotal factors.
There is rise in global incidence of bleeding disorders necessitating the utilization of human fibrinogen concentrates, particularly in critical surgical procedures where efficient hemostatic agents are indispensable. Concurrently, advancements in biotechnology have ushered in the development of more sophisticated formulations of human fibrinogen concentrates, characterized by enhanced efficacy and safety profiles, thereby amplifying their demand. Furthermore, rise in awareness among healthcare practitioners and patients regarding the therapeutic advantages of fibrinogen concentrate is fostering its adoption, particularly within clinical settings.
Hence, these factors are poised to drive substantial growth in the human fibrinogen concentrate market during the forecast period. By indication, the congenital fibrinogen deficiency segment dominated the market in 2023 and is expected to continue this trend du.